EnWave Corporation
TSX VENTURE : ENW
FRANKFURT : E4U

EnWave Corporation

March 06, 2008 16:00 ET

EnWave Provides Progress Report on Aridis Collaboration Testing of Vaccine Dehydration Technology

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 6, 2008) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or the "Company") today reported that Aridis Pharmaceuticals, LLC ("Aridis") of San Jose, California has completed its first testing stage of the bioREV technology for use as a vaccine and antibody dehydration method.

Aridis is testing EnWave's bioREV technology, under a Collaboration Agreement between the two companies, to determine the feasibility of using this proprietary technology to dehydrate vaccines and antibodies to produce room temperature, shelf-stable pharmaceuticals as a cost-effective alternative to the industry standard of lyophilization (freeze drying). EnWave believes that the production of dried vaccines and antibodies storable at room temperature could lead to an industry breakthrough by allowing these pharmaceuticals to be shipped worldwide, stored without the need for expensive refrigeration, and stockpiled to protect against pandemic diseases and bioterrorism threats.

The goals of the Aridis testing program are to establish bioREV processing parameters for optimizing vaccine bioactivity and stability in a dehydrated state. Bioactivity refers to the amount of vaccine survival retained after drying, while stability refers to the ability of the dehydrated vaccine to retain an acceptable level of survival during an extended storage period. Accomplishing both of these goals after bioREV processing is important for establishing a feasible method of dehydration.

During the first stage of testing, Aridis ran comprehensive tests on the bioREV single-vial process to evaluate the impact of power, rotation speed, vacuum, temperature and process time when dehydrating live attenuated salmonella typhoid ("Ty21a") and rotavirus vaccines. Ty21a is the parent vaccine vector for Aridis' anthrax and shigella vaccines. The initial testing also included the introduction of a number of formulation stabilizers to improve stability and determine stabilizer impact during processing.

Initial test results indicated bioREV was able to successfully dry both vaccines with promising bioactivity retention. However, a residual moisture content in excess of the requirements was identified as a potential limitation for achieving long-term shelf stability. Although initial stability testing was initiated on Aridis's rotavirus vaccine with excellent short-term results to date, EnWave and Aridis have now agreed to introduce a number of equipment improvements and new vaccine formulation stabilizers with the goal of reducing the final vaccine moisture from the current range of 5-6% to a target closer to 3%.

"We are encouraged by the initial testing results and bioREV's unique range of processing flexibility," stated Dr. Vu Truong, Aridis' Vice President of R&D. "Conventional freeze drying technologies are not capable of achieving long-term room temperature stability for the Ty21a vaccine, and we are committed to working together with EnWave to find a commercially viable alternative to freeze drying vaccines and antibodies."

During the next six months, EnWave has budgeted an additional CDN$120,000 to complete process improvements and expand testing at both its own lab and the Aridis facility. The objective is to optimize the formulation and process parameters to complete a final viability review for the Ty21a and rotavirus vaccines by the end of September 2008.

Until this work has been completed, EnWave has decided to defer building its multi-vial bioREV technology to ensure all of the design opportunities learned from the process improvements and expanded testing are incorporated. Under this revised schedule the delivery of the multi-vial technology is expected in the 2nd quarter 2009 with completion of the Aridis collaboration in the 3rd quarter of 2009.

"EnWave has already initiated a number of process improvements for reducing final vaccine moisture," said Dr. Tim Durance, EnWave's Chairman and Co-CEO. "This expanded testing program will provide us with further concrete data on the viability of bioREV technology and the long-tem stability of dehydrated vaccines that we can present to potential partners in the pharmaceutical and biotech industry."

About Aridis

Aridis is a privately held biopharmaceutical company formed in 2003, which uses pioneering formulation, processing, and delivery technologies to produce differentiated, high value products. Aridis' goal is to develop therapeutics and vaccines that are more convenient and cost effective for both the recipient and the health professional by simplifying their storage and administration. Their initial products target infectious diseases that have a significant impact on life expectancy, such as infectious diseases in children and cystic fibrosis (CF) in adults and children. Aridis has four licensed products: three with preclinical data, and one with phase II clinical efficacy data. More information about Aridis is available at www.aridispharma.com.

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating biological and food materials using Radiant Energy Vacuum technology under its bioREV and nutraREV brands. REV technology combines microwave energy transfer with pressure control to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include dry vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation

Dr. Tim Durance, Chairman & CO-CEO

Safe Harbour for Forward-Looking Information Statements: This release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Forward looking statements in this press release include: "expects to receive" and "hope to prove". These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's bioREV technology will be developed as a commercial-scale method for dehydrating vaccines and antibodies; even if the Company's bioREV technology can be used as described in this news release, there is no guarantee that such use will result in orders for the Company's bioREV technology. There is no guarantee that the patent subject of this press release will be granted.

The TSX Venture Exchange has neither approved nor disapproved the information contained herein.

Contact Information

  • EnWave Corporation
    Dr. Tim Durance
    Chairman and Co-CEO
    (604) 601-8524
    or
    EnWave Corporation
    Mr. John McNicol
    President and Co-CEO
    (604) 601-8524
    (604) 806-6112 (FAX)
    or
    EnWave Corporation
    Martin Livingston
    Investor Relations
    (604) 657-8234
    Website: www.enwave.net